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The epidermal growth factor receptor- (EGFR-) directed antibody, cetuximab, was FDA-approved for the treatment of squamous
cell carcinoma of the head and neck (SCCHN) in 2006. Additional EGFR-targeting agents in clinical development for SCCHN
include other EGFR-directed antibodies, tyrosine kinase inhibitors and antisense DNA. Although the majority of SCCHN
overexpress EGFR, SCCHN clinical responses to EGFR-targeting agents have been modest. Molecular predictors for SCCHN
response to EGFR-targeted therapies have not been identified. However, molecular correlate studies in lung cancer and colon
cancer, which have EGFR-targeted therapeutics FDA-approved for treatment, may provide insights. We describe candidate
predictive markers for SCCHN response to EGFR-targeted therapies and their prevalence in SCCHN. Clinical response will
likely be improved by targeted therapy combination treatments. Src family kinases mediate EGFR-dependent and -independent
tumor progression pathways in many cancers including SCCHN. Several Src-targeting agents are in clinical development for solid
malignancies. Molecular correlate studies for Src-targeting therapies are few and biomarkers correlated with patient response are
limited. Identifying SCCHN patients who will respond to combined EGFR- and Src-targeting will require further characterization
of molecular correlates. We discuss rationale for EGFR and Src co-targeting for SCCHN treatment and describe recent clinical
trials implementing combined Src- and EGFR-targeted therapeutics.
Copyright © 2009 A. M. Egloff and J. R. Grandis. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. Introduction
Ninety-percent of head and neck cancers are squamous cell
carcinomas (SCCHN) involving the mucosal surfaces of the
oral cavity, pharynx, and larynx. The overall relative 5-year
survival rates for cancers of the oral cavity/pharynx and
larynx are estimated to be 58.3% and 64.5%, respectively
[1]. Morbidities associated with SCCHN and its treatments
are significant and include eating and swallowing difficulties.
Targeted therapies for SCCHN are under active investigation
with the goals of reducing SCCHN morbidity and mortality.
Targeted therapeutics were conceptualized as a means
of exploiting specific molecular alterations associated with
cancers in order to selectively kill transformed cells and spare
normal, healthy tissues. Targeted therapies are anticipated
to have fewer associated toxicities than standard chemother-
apies, which rely predominately on increased rates of cell
division to enhance killing of the tumor cells compared to
healthy tissues. For tumors that are treated with radiation
and/or surgery, targeted therapies delivered systemically
also have the potential to eliminate micrometastases that
might not be eliminated with radiation therapy (RT) and/or
surgery. In addition to reduced toxicity and treatment of
undetected disease, it is hypothesized that effective targeted
therapy may interfere specifically with processes that the
cancer is dependent upon and be more effective than
conventional therapies.
The epidermal growth factor receptor (EGFR) was antici-
pated to be a good drug target for SCCHN treatment because
the majority of SCCHN overexpress EGFR [2, 3], and higher
tumor levels of EGFR are associated with poorer clinical
outcomes [4, 5]. EGFR participates in SCCHN autocrine
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stimulation, and overexpression of EGFR and its primary lig-
and in humans, transforming growth factor alpha (TGF-α),
have been correlated with poor outcomes for patients receiv-
ing therapy [5]. Cetuximab (Erbitux; ImClone Systems), a
chimeric monoclonal IgG1 antibody directed against EGFR,
was FDA-approved for the treatment of SCCHN in com-
bination with RT for locally or regionally advanced disease
and as a monotherapy for recurrent or metastatic SCCHN
patients who have failed prior platinum-based therapy [6]. In
addition to antibodies directed against EGFR, small molecule
tyrosine kinase inhibitors (TKI) of EGFR and EGFR anti-
sense agents are currently under active clinical investigation
for SCCHN treatment. EGFR-targeted therapeutics delivered
as monotherapies for treatment of SCCHN have demon-
strated fewer toxicities compared to combined modality
treatment regimens but only marginal clinical response (4–
10%) [7, 8]. In general responses to EGFR-targeted therapies
in SCCHN clinical trials have been modest.
Improving clinical response rates will involve (1) identi-
fying SCCHN patients who are likely to respond to EGFR-
targeted therapies, (2) developing effective combinations of
targeted therapies, and (3) correctly identifying patients who
will respond to specific targeted agents applied alone or in
combination. Our understanding of the factors contributing
to targeted therapy response now extends beyond the
molecular alterations of the tumor to include host genetic
variation. In this review, we will summarize molecular data
correlated with clinical response to EGFR-targeted therapies
and discuss factors that may be considered for identifying
responsive SCCHN patients. Preclinical evidence suggests
that Src family kinase-targeted agents administered in com-
bination with EGFR-targeted therapies may demonstrate
improved clinical response over EGFR-targeted agents alone.
Here we also provide rationale for combining EGFR- and
Src-targeted therapeutics for treatment of SCCHN, discuss
published EGFR- and Src-combination treatment preclinical
data, and summarize completed and ongoing clinical trials
in solid tumors evaluating Src-targeted therapies in combi-
nation with EGFR-targeted therapies.
2. EGFR-Targeted Therapies for SCCHN
There are several EGFR-targeted therapies in clinical devel-
opment for SCCHN, and these agents are described in
Table 1. These inhibitors fall into two primary cate-
gories: EGFR-directed antibodies and EGFR tyrosine kinase
inhibitors. EGFR-directed antibodies include cetuximab,
nimotuzumab (YM Biosciences), panitumumab (Amgen),
and zalutumumab (GenMab). EGFR-targeted tyrosine
kinase inhibitors include erlotinib (Genetech and OSI Phar-
maceuticals) and gefitinib (AstraZeneca). In addition to
EGFR-targeted kinase inhibitors, inhibitors with broader
target specificities are also in Phase II or III development
for SCCHN including lapatinib (GlaxoSmithKline), which
is a dual EGFR/HER2 inhibitor, and zactima (AstraZeneca),
which targets VEGFR2 and RET in addition to EGFR
(Table 1). More recently antisense therapy targeting EGFR
has been evaluated in a Phase I clinical trial by our group [9].
Results of clinical trials for EGFR-targeted therapies
cetuximab, nimotuzumab, gefitinib, and erlotinib used alone
or in combination with conventional treatments for SCCHN
have been reviewed by us and others and will not be
described in detail here [10–12]. A Phase I study of panitu-
mumab in combination with chemoradiotherapy involving
19-treatment-naı¨ve patients with stage III/IV head and neck
cancer reported an 87% complete response rate among the 15
evaluable patients and no grade 3 or 4 chronic toxicities [13].
A Phase I study of lapatinib in combination with chemoradi-
ation in 31 patients with locally advanced SCCHN reported
an overall response rate of 81% with radiation-associated
mucositis, dermatitis, lymphopenia, and neutropenia as the
most common grade 3 or 4 adverse events [14]. Our Phase
I study of intratumoral delivery of EGFR antisense DNA in
17 patients with advanced, refractory SCCHNwas associated
with no grade 3 or 4 or dose-limiting toxicities and a clinical
response rate (complete response and partial response by
modified RECIST criteria) of 29% [9]. The current phase of
clinical development for each of these agents is presented in
Table 1.
3. Predictors of Response to
EGFR-Targeted Therapies
To date, no molecular marker has been identified to corre-
late with SCCHN response to EGFR-targeting in patients.
SCCHN tumor expression of the truncated form of EGFR,
EGFR variant III (vIII), which lacks the ligand binding
domain, occurs in up to 40% of SCCHN tumors and con-
fers resistance to EGFR-targeted monoclonal antibodies in
SCCHN preclinical models [15]. However, EGFR vIII expres-
sion and resistance to EGFR-targeted therapies in SCCHN
patients has not been described. Molecular correlates of
clinical response/nonresponse to EGFR-targeted therapies
have been identified for colon and lung cancers. For example,
the treatment of lung cancer with the EGFR tyrosine kinase
inhibitor gefitinib demonstrated effective responses in a
subset of patients whose lung cancers were subsequently
found to harbor EGFR kinase activating mutations [16, 17].
Importantly, EGFR activating mutations do not appear to
be frequent in SCCHN [18, 19]. Therefore, some of these
molecular correlates, such as the EGFR tyrosine kinase
activating mutations are not applicable to SCCHN because
the frequency of these mutations is very low and will
not be discussed further in this review. However, other
molecular correlates of response to EGFR-targeting agents
have been described for lung cancer and colorectal cancers
including EGFR gene amplification, other somatic tumor
mutations and patient genetic variations. These biomarkers
have potential utility as predictive markers for SCCHN.
3.1. Tumor EGFR Gene Amplification. EGFR gene amplifi-
cation occurs in SCCHN, and the rate of reported EGFR
gene amplification in SCCHN varies substantially (Table 2).
To date, there are no published reports evaluating EGFR
gene amplification for association with SCCHN patient
response to EGFR-targeted therapies. However, EGFR gene
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Table 1: EGFR-targeted therapies in clinical development for SCCHN.
Agent Sponsor Class FDA-approval
Clinical trial phase for
SCCHN
Antibodies
Cetuximab
C225,
Erbitux
ImClone Systems Chimeric IgG1
SCCHN; colorectal
cancers
III
Nimotuzumab h-R3 YM Biosciences Humanized IgG1 —
IV Advanced disease;
II Locally advanced
disease
Panitumumab
ABX-EGF;
Vectibix
Amgen Fully human IgG2 Colorectal cancers III
Zalutumumab
HuMax-
EGFR
GenMab Fully human IgG1 — III
Tyrosine kinase inhibitors
Erlotinib
Tarceva;
OSI-774
Genetech and OSI
Pharmaceuticals
Reversible ATP competive Lung cancer III
Gefitinib
ZD-1839;
Iressa
AstraZeneca Reversible ATP competive
Lung cancer,
relabeling limits
III
Lapatinib Tykerb GlaxoSmithKline
Reversible ATP competitive
dual EGFR/Her2
Breast cancer III
Zactima ZD6474 AstraZeneca
Reversible ATP competitive
VEGFR-2, EGFR and RET
— II
amplification has been reported to be positively associ-
ated with response to EGFR-directed antibody therapies
in clinical trials for nonsmall lung cancers (NSCLC) and
colorectal cancers. In a phase II study of 229 NSCLC patients
with advanced-stage NSCLC treated with cetuximab plus
chemotherapy, 76 patient tumors were evaluated for EGFR
gene amplification by FISH and disease controls rate (com-
plete response/partial response and stable disease) was found
to be significantly higher in patients with FISH-positive
tumors compared to FISH-negative tumors (81% versus
55%, P = .02). In this same study, median progression-
free survival was also significantly longer for patients with
FISH-positive tumors compared to FISH-negative tumors
(6 months versus 3 months, P = .0008) [20]. Several
studies have reported positive associations between EGFR
gene amplification and metastatic colorectal cancer response
to EGFR-directed antibodies [21–23].
EGFR gene amplification in SCCHN has been reported
range between 10–58% of SCCHN (Table 2) [24–32]. The
range of reported prevalence of EGFR gene amplification
may be due to differences in expression by tumor anatom-
ical site. However, several methods were used to assess
EGFR gene amplification, including fluorescence in situ
hybridization (FISH) and quantitative real-time polymerase-
chain reaction- (Q-PCR-) based assays. In addition, different
scoring methods were employed in the studies presented in
Table 2, some of which included polysomy in the definition
for EGFR amplification and others did not. These differ-
ences in methodologies likely contribute to the variation
in reported rates of EGFR gene amplification in SCCHN.
The presence of EGFR gene amplification in a substantial
portion of SCCHN and the previously reported associations
between EGFR gene amplification and response to EGFR-
targeted therapies in other cancers suggest that EGFR gene
amplification may be a predictive marker for response to
EGFR-targeted therapies in SCCHN. When evaluating EGFR
gene amplification for correlation with response to EGFR-
targeted agents, it will be important to develop consensus
definitions of EGFR gene amplification.
EGFR gene amplification has not consistently been
reported to correlate with EGFR protein levels although a
plausible mechanism for gene amplification without protein
overexpression is lacking [25, 28–30] (Table 2). In NSCLC
and colon cancers a positive association between EGFR
gene amplification and protein expression has also not
been consistently observed [44, 45]. Importantly, EGFR
gene amplification status, but not EGFR tumor protein
levels, is associated with response to EGFR-targeted thera-
pies in NSCLC and colorectal cancers. These discrepancies
likely reflect the semiquantiatitve and variable methods of
assessing gene amplification and protein expression lev-
els in various laboratories. The characterization of EGFR
gene amplification in SCCHN patients treated with EGFR-
directed antibodies and the testing of association with
response to therapy will be of interest.
3.2. Tumor KRAS/HRAS Mutations. Ras proteins are small
GTPases that regulate signal transduction pathways leading
to cell growth, differentiation, and survival. Three RAS genes
produce four Ras proteins, KraS 4A, KraS 4B, H-Ras, and N-
Ras, that are more than 90% homologous but demonstrate
a high degree of tumor-type mutation specificity [46]. KRAS
mutations have been reported by several independent groups
to be negatively associated with response to EGFR tyrosine
kinase inhibitors in lung cancer and EGFR-directed anti-
bodies in colon cancer. A metaanalysis including 17 NSCLC
EGFR tyrosine kinase inhibitor clinical studies with 1008
patient tumors and 8 metastatic colorectal cancer (mCRC)
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Table 2: Candidate predictive markers for SCCHN response to EGFR-targeted therapies.
Tumor
molecular
marker
Study/
reference
Tumor
type(s)
N tumors
assessed
N tumors with
molecular
marker
Assay method
Positive scoring
definition(s)
Associated with
EGFR tumor levels
EGFR gene
amplification
Sheu et al.,
2009 [24]
OSCC 128 22 (17.2%) FISH
>2.5 EGFR signals relative
to Cen7 signal
Yes
Ch’ng et al.,
2008 [25]
SCCHN 39 18 (46%) FISH
>2 EGFR signals relative to
Cen7 signals or ≥15 EGFR
copies per cell in ≥10% of
cells
No
Chiang et al.,
2008 [26]
OSCC 42 14 (33%) Q-PCR
≥2 EGFR gene copies
relative to LINE1 element
No
Temam et al.,
2007 [27]
SCCHN 134 22 (17%)
Q-PCR (n = 134)
and FISH (n = 16)
Q-PCR: >mean + 1.96
standard deviations of
normal WBC EGFR gene
copy number normalized
to β-globin; FISH: ≥4 gene
copies in 40% of cells or
gene/chromosome ratio >2
or ≥15 gene copies in
≥10% of cells
No significant
correlation
between EGFR
gene amplification
by FISH and EGFR
IHC expression
Chung et al.,
2006 [28]
SCCHN 75 43 (58%) FISH
≥4 gene copies in 40% of
cells or gene/chromosome
ratio >2 or ≥15 gene copies
in ≥10% of cells
No
Hanawa et
al., 2006 [29]
ESCC 106 53 (50%) FISH EGFR signal > Cen7 signal Yes
Mrhalova et
al., 2005 [30]
SCCHN 33 7 (21%) FISH No
Koynova et
al., 2005 [31]
Larynx
cancers
1080 112 (10.4%) FISH
≥4 EGFR signals relative to
Cen7 in ≥10% of cells NA
Freier et al.,
2005 [32]
SCCHN 609 12.70% FISH
≥8 EGFR signals relative to
Cen7 in ≥10% of cells NA
KRAS
mutations
Sheu et al.,
2009 [24]
OSCC 29 2 (6.9%) Sequencing KRAS Q61H mutation NA
Lea et al.,
2007 [33]
ORAL
cancers
122 5 (4%)
GAC database
analysis
Somatic missense,
nonsense, silent point
mutations, frameshift and
in-frame deletions and
insertions
NA
Forbes et al.,
2008 [34]
Oral,
pharynx,
larynx
cancers
937 24 (3%) COSMIC database
Datamining of published
reports and somatic
mutation screening from
Cancer Genome Project
NA
HRAS
mutations
Forbes et al.,
2008 [34]
Oral,
pharynx,
larynx
cancers
686 75 (10%) COSMIC database
Datamining of published
reports and somatic
mutation screening from
Cancer Genome Project
NA
Lea et al.,
2007 [33]
ORAL
cancers
170 19 (11%)
GAC database
analysis
Somatic missense,
nonsense, silent point
mutations, frameshift and
in-frame deletions and
insertions
NA
Anderson et
al., 1994 [35]
ORAL
cancers
35 6 (22%)
PCR and
restriction length
polymorphism
analysis
Presence of appropriately
altered restriction enzyme
digested DNA fragment
NA
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Table 2: Continued.
Tumor
molecular
marker
Study/
reference
Tumor
type(s)
N tumors
assessed
N tumors with
molecular
marker
Assay method
Positive scoring
definition(s)
Associated with
EGFR tumor levels
PI3KCA
mutations
Murugan et
al., 2008 [36]
SCCHN 37 2 (5%)
PCR and direct
sequencing exons 9
and 20
Somatic missense,
nonsense, frameshift,
in-frame deletions, and
insertions
NA
Fenic et al.,
2007 [37]
SCCHN 33 0 (0%)
PCR and direct
sequencing exons 9
and 20
Somatic missense
mutations
NA
Qiu et al.,
2006 [38]
SCCHN 38 4 (11%)
PCR and direct
sequencing exons
1, 4, 5, 6, 7, 9, and
20
Somatic missense
mutations
NA
Kozaki et al.,
2006 [39]
OSCC 108 8 (7%)
PCR and direct
sequencing exons 9
and 20
Somatic missense
mutations
NA
PTEN
mutations
Shin et al.,
2002 [40]
OSCC 86 4 (5%)
PCR and exon
direct sequencing
Somatic missense,
nonsense, silent point
mutations, frameshift,
in-frame deletions, and
insertions
NA
Poetsch et al.,
2002 [41]
SCCHN 52 7 (13%)
PCR and exon
direct sequencing
Somatic missense,
nonsense, frameshift,
in-frame deletions, and
insertions
NA
Mavros et al.,
2002 [42]
OSCC 50 0 (0%)
PCR and exon
direct sequencing
Somatic missense,
nonsense, frameshift,
in-frame deletions, and
insertions
NA
Shao et al.,
1998 [43]
SCCHN 19 3 (16%)
PCR and exon
direct sequencing
Somatic missense,
nonsense, frameshift,
in-frame deletions, and
insertions
NA
Squamous cell carcinoma of the head and neck (SCCHN), oral squamous cell carcinoma (OSCC), esophageal squamous cell carcinoma (ESCC), fluorescence
in situ hybridization (FISH), quantitative real-time polymerase chain reaction (PCR), centromere 7 (Cen7), Genetic Alterations in Cancer (GAC) database,
and the Catalogue of Somatic Mutations in Cancer (COSMIC) database.
studies of anti-EGFR monoclonal antibody-based therapies
in 817mCRC patients found that KRAS mutations were
significantly associated with absence of response to EGFR-
targeted therapies for these cancers [47]. KRAS mutations
are especially important predictors of unresponsiveness to
EGFR-directed antibodies in colorectal cancers with EGFR
gene amplification [48]. Reported rates of KRAS mutations
in NSCLC range between 8–20% with higher rates reported
for adenocarcinoma compared to squamous cell carcinoma
histologies [49, 50]. KRASmutations occur in approximately
30% of colon cancers [51].
KRAS mutations are relatively rare in SCCHN. Only
one published report has described KRAS mutations in
SCCHN to date, and in this analysis of 29 oral squamous
cell carcinoma tumors, 9 (6.9%) were found to harbor
KRASmutations [24]. According to the Catalogue of Somatic
Mutations in Cancer (COSMIC) database from the Sanger
Institute, KRAS mutations occur in only approximately 3%
of all cancers of the oral cavity, pharynx, or larynx while
HRAS mutations occur in 10% of these cancers (Table 2)
[34]. These rates are similar to data from the Genetic
Alterations in Cancer (GAC) database presented in Table 2
[33]. The recent finding that a mouse knock-in model
expressing HRAS from the KRAS chromosomal context
accumulated HRASmutations and resulted in increased lung
tumorigenicity suggests that tissue-specific expression of
KRAS and HRAS likely contributes to tumor-type specificity
of mutations in these two genes [52]. To date, only one
published study of HRASmutations SCCHN reported a 22%
rate of mutations in oral squamous cell carcinoma (Table 2)
[35]. Mutations in HRAS are likely to be more common
in SCCHN than KRAS mutations and may be important
correlates for lack of response to EGFR-targeted therapies in
SCCHN.
3.3. Tumor PI3K-AKT Pathway Mutations. Phosphatidyli-
nositol 3-kinases (PI3Ks) are heterodimeric kinases com-
posed of regulatory and catalytic subunits that are involved
in the control of cell proliferation, survival, and motility.
The PI3K catalytic subunit, P110alpha (PIK3CA) has been
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reported to be somatically mutated and activated in several
cancers including SCCHN. Activation of PIK3CA leads to
plasma membrane recruitment and activation of Akt and
downstream survival mechanisms. PIK3CA mutations have
been reported to be associated with resistance to EGFR-
targeted monoclonal antibodies in patients with metastatic
colorectal cancers (mCRC). In a study involving 110 patients
with mCRC, PIK3CA mutations were found to be sig-
nificantly associated with reduced objective response rates
following treatment with cetuximab or panitumumab (P =
.038) and shorter progression-free survival (P = .035) [53].
PIK3CA mutations have been reported to occur in up to 8%
of SCCHN as summarized in Table 2 [36–39].
PI3K signaling is inhibited by the activity of the
phosphatidylinositol phosphatase, PTEN. PTEN acts as a
tumor suppressor by negatively regulating the Akt signaling
pathway. PTEN mutations occur in colorectal, lung, and
head and neck cancers. Additionally, loss of PTEN expression
occurs by mechanisms including promoter methylation
and silencing or loss of heterozygosity. In SCCHN, PTEN
mutations are not common (Table 2) [40–43], and loss
of heterozygocity of PTEN has been reported to occur in
approximately 12% of SCCHN [42]. Though the association
with response to EGFR-targeted therapy inmCRC and loss of
PTEN expression does not appear to be as strongly correlated
as response and PIK3CAmutations [53], the consideration of
both tumor PTEN expression status and PIK3CA mutation
status may contribute to predicting response to EGFR-
targeted therapies in SCCHN.
3.4. EGFR Polymorphisms. Several EGFR polymorphisms
have been reported to be associated with differential response
to EGFR-targeted therapies. In lung cancer, shorter EGFR
intron 1 CA repeat polymorphism has been reported to
be associated with improved response to gefitinib in two
independent studies [54, 55]. In one study involving 70
patients with advanced NSCLC, patients with fewer than 17
CA repeats at either allele had significantly longer survival
following treatment with gefitinib than patients having both
alleles greater than 16 CA repeats (P = .039) [54]. Fewer
EGFR intron 1 CA repeats were also significantly associated
with mCRC patient response to cetuximab-based treatment
in a study involving 110mCRC patients receiving combined
cetuximab-irinotecan salvage therapy [56]. An independent
study of 139 NSCLC patients with WHO performance status
of 0 or 1 who received gefitinib reported that patients with
the EGFR haplotype of −216G/−191C had significantly
worse survival with a hazard ratio of 1.85 (95% CI: 1.09
to 3.12) after adjusting for performance status, previous
platinum treatment, skin rash, and diarrhea [57]. The EGFR
intron 1 CA repeat polymorphism has been reported to
affect EGFR basal transcription with higher transcription
rates reported in individuals with fewer CA repeats [58, 59].
Differential promoter activity has also been reported for
the two most common EGFR haplotypes at the −216G
> T and −191C > A with the −216G/−191C haplotype
having lower promoter activity and mRNA expression [60,
61]. These studies, therefore, indicate that patient EGFR
polymorphisms associated with higher EGFR expression are
more likely to respond to EGFR-targeted therapies.
The presence of the EGFR K521R variant has also
been found to be associated with significantly improved
progression-free survival (PFS) and overall survival (OS) in
32 EGFR-positive mCRC patients treated with cetuximab in
combination with irinotecan [62]. Patients with the K521R
variant had significantly longer PFS than patients with wild-
type EGFR, 5.7 months versus 3.2 months, respectively, (P =
.04, log rank test) and OS, 20.1 months versus 13.8 months,
respectively, (P = .03) [62]. This EGFR variant, which
resides in the extracellular domain of EGFR, has reduced
ligand-binding, growth-stimulation, and kinase activity in
vitro for the 521K variant. These findings suggest that EGFR
polymorphisms have the potential to be correlated with
response to EGFR-targeted therapies in SCCHN.
3.5. FCγRIIa and FCγRIIIa Polymorphisms. Cetuximab, a
chimeric monoclonal IgG1 anti-EGFR antibody (Table 1),
may exert its antitumor effects via several mechanisms
including antibody-dependent cell mediated cytotoxicity
(ADCC). The fragment c (Fc) portion of IgG1 antibodies
can be recognized by the Fc gamma receptors (FCγR) on
immune effector cells to induce ADCC. Polymorphisms in
FCγRIIIa have been shown to be associated with differential
response to cetuximab in mCRC patients in clinical studies
and to SCCHN cell lines in vitro [63–65]. The FCγRIIIa
polymorphism-V158F variant 158V was found to have
higher cetuximab-mediated ADCC in vitro [64, 65]. The
158V variant was also associated with longer PFS in a
study involving 69mCRC patients treated with cetuximab
plus irinotecan [63]. These findings indicate that FCγRIII
variants may contribute to response to cetuximab in SCCHN
patients.
The ability to correctly predict which patients will
respond to which EGFR-targeted therapy will improve
clinical response and reduce treatment-associated toxicities
for these patients. However, the minority of SCCHN patients
have responded to EGFR-targeted therapies in clinical trials,
indicating that even if patients likely to respond to EGFR-
targeted therapy were identified, they would represent a small
portion of SCCHN patients. Even though the majority of
SCCHN cancers overexpress EGFR, these tumors are not
solely dependent upon EGFR activity. This is likely due to the
presence of preexisting or treatment-induced compensatory
signaling pathways. Because EGFR is activated in SCCHN
and response to EGFR-targeted therapies has been demon-
strated in clinical trials, it is reasonable to consider targeted
therapies to be used in combination with EGFR-targeted
therapeutics. Molecular signaling pathways in SCCHN that
can be activated independently of EGFR include pathways
initiated by G-protein-coupled receptors, integrins, and
other receptor tyrosine kinases. Many of these pathways
share Src family kinases (SFK) as downstream mediators of
signaling. For these reasons, SFK have been identified as
viable candidates for targeting in combination with EGFR.
The combination of SFK- and EGFR-targeted agents for
treatment of SCCHN is anticipated to have improved clinical
efficacy compared to EGFR-targeting agents alone.
Journal of Oncology 7
Table 3: Src-targeting agents in clinical development.
Agent Sponsor Target(s)
SFKs
targeted
(IC50)
Target site Irreversible
Solid cancers in
phase II or III
clinical study∗
FDA approval
(Date)
SCCHN
clinical trial
phase
Dasatinib
BMS-
354825
Bristol-Myers
Squibb
Src; Abl;
c-Kit;
PDGFR;
others
ATP-
binding
No
SCLC, NSCLC,
breast,
colorectal, head
and neck, liver,
melanoma,
ovarian,
pancreatic,
sarcoma
Chronic
myeloid
leukemia (June
2006)
II
AZD0530 AstraZeneca Src; Abl
ATP-
binding
No
SCLC, NSCLC,
breast,
colorectal, head
and neck,
melanoma,
osteosarcoma,
ovarian,
pancreatic,
prostate
— II
Bosutinib SKI-606 Wyeth Src; Abl
ATP-
binding
No Breast — —
KX01
KX2-
391
Kinex Src
Peptide-
binding
No (phase I) — —
XL999 Exelixis
Src,
VEGFR,
PDGFR,
FGFR,
FLT-3,
others
ATP-
binding
No
NSCLC,
colorectal,
kidney, ovarian
— —
∗ClinicalTrials.gov solid tumors.
4. Src Family Kinases in SCCHN
Eight Src nonreceptor protein tyrosine kinase family mem-
bers are expressed in humans: c-Src, Blk, Fgr, Fyn, Hck,
Lck, Lyn, and c-Yes. c-Src, Fyn, Lyn, and c-Yes are broadly
expressed, while Blk, Fgr, Hck, and Lck expression is pri-
marily restricted to hematopoietic cells [66]. Src kinases have
been implicated in normal cellular functions including cell
adhesion, migration, angiogenesis, survival, proliferation,
and differentiation [67, 68]. When these processes are inap-
propriately regulated, they can contribute to tumorigenesis,
tumor progression and metastases. In SCCHN models,
Src kinases are activated in response to EGFR stimulation
[69], associate with EGFR [69], and have reduced activity
following EGFR inhibition in vitro [70]. Src kinases are
also upstream activators of EGFR and other receptor tyro-
sine kinases (RTKs). Following G-protein-coupled receptor
(GPCR) stimulation, Src kinases are activated, resulting in
the release of RTK ligands [71, 72]. In addition to RTKs
and GPCRs, Src kinases are also activated by integrins in
SCCHN [73]. Src kinases, therefore, are involved in the
autocrine/paracrine stimulation of SCCHN and mediate
EGFR-dependent and EGFR-independent signaling events.
Of the Src family kinases (SFK), c-Src is the most studied
and most often implicated in cancer. Elevated c-Src protein
and/or kinase activity has been reported for cancers of the
lung, colon, breast, ovary, and pancreas in addition to head
and neck cancers [68, 74]. c-Src is rarely mutated in cancer
[74–76]. Therefore, increased activity of upstream signaling
components and/or decreased activity of c-Src negative
regulators are likely causes of c-Src activation observed in
many epithelial cancers.
The expression and activation of specific SFK in SCCHN
are less well understood. The SFK c-Src, Fyn, Lyn, and c-
Yes are activated in SCCHN cell lines in vitro following
stimulation with the EGFR ligand TGF-α [69], and these
SFK likely play roles in SCCHN. At least one group has
reported differential response of SFK to integrin β6 signaling
following simulation with fibronectin, the integrin β6 ligand,
in oral squamous cell carcinoma cell lines. Integrin β6, which
is neoexpressed in SCCHN, has been found to activate
Fyn but not c-Src or c-Yes in SCCHN upon ligation with
fibronectin, leading to Fyn-dependent activation of the Raf-
ERK/MAPK pathway [73]. The murine knock-out models
of specific SFK provide insights into the different roles of
the individual SFK. The functions of some of the SFKs
are redundant, at least regarding mouse development, as
evidenced by lack of phenotype for single knock-out models
of c-yes, hck, c-fgr, and blk [66]. The single knock-out
murine models of lyn and lck had immune impairments,
fyn knock-out mice exhibited defective brain development
and impaired memory and immune functions, and c-src
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null mice developed a bone remodeling disease with excess
accumulation of bone [66]. Therefore, some functions are
likely shared between the four SFKs with a subset of
functions that may be unique to selective SFK.
5. Src Family Kinases in SCCHN Invasion
and Progression
Mortality from SCCHN is usually associated with tumor
invasion and locoregional metastases. The major site of
SCCHN metastases is locoregional lymph nodes, and pres-
ence of neck lymph node metastases is universally accepted
as the most important prognostic indicator for SCCHN. The
development of metastases requires that cells move from the
primary tumor and invade surrounding tissues. Invasion by
tumor cells is preceded by the loss of cell adhesion and the
gain of mesenchymal features in a process similar to events
that occur in development termed epithelial-mesenchymal
transition (EMT) [77]. EMT is accompanied by the loss of
E-cadherin, which is a principal component of cell adhesion
complexes, and the gain of mesenchymal characteristics
including expression of vimentin [77].
The activation of Src kinases has been shown to be
involved in EMT in cancer [78]. More recently, a study evalu-
ating 50 primary SCCHN tumors for activated phospho-Src
(P-Src), E-cadherin, and vimentin expression by immuno-
histochemical staining found increased P-Src, decreased E-
cadherin, and presence of vimentin expression in SCCHN
tumors to be significantly associated (P < .05) with
morphologies associated with aggressive cancers including
penetrating invasive fronts, poor or sarcomatoid differentia-
tion, and lymph node metastases [79]. It is important to note
that the P-Src antibody used in this study recognizes several
activated SFKs and is not specific for P-c-Src. In addition to
studies in SCCHN tumors, preclinical studies indicate that
SFKs are involved in SCCHN migration and invasion. Our
group found that blockage using an Src-specific inhibitor
A-419259 resulted in decreased invasion and growth of
SCCHN cell lines in vitro following stimulation with a GPCR
ligand, gastrin-releasing peptide [72]. An independent group
reported that dasatinib (Sprycel, BMS-34825; Bristol-Meyers
Squibb), a dual Src/Abl kinase inhibitor (Table 3), inhibited
migration and invasion in vitro in all 8 SCCHN cell lines
evaluated [80]. Together these studies implicate an important
role or roles for SFK in tumor migration and invasion, which
are associated with increased mortality in SCCHN. Which
SFKs are activated in SCCHN migration and invasion is cur-
rently not known. Importantly, epithelial tumor cells includ-
ing SCCHN that have undergone EMT and acquired mes-
enchymal characteristics are more resistant to EGFR-targeted
therapies than tumor cells that have epithelial characteristics
[81]. Combining Src-targeted agents with EGFR-targeted
therapies may be more effective than EGFR-targeted thera-
pies alone for the control of SCCHN locoregional metastases.
6. Src-Targeting Agents in Clinical Development
Several small molecule inhibitors of c-Src and SFK are
currently in clinical development for solid tumors including
dasatinib (Sprycel, BMS), AZD0530 (AstraZeneca), bosu-
tinib (SKI-606; Wyeth), XL999 (Exelixix), and KX01 (Kinex)
(Table 3). All of these inhibitors are reversible inhibitors, and
all except KX01 are ATP-competitive inhibitors (Table 3).
These inhibitors differ primarily in their target specifici-
ties. Dasatinib and XL999 target several known kinases in
addition to SFK (Table 3), while AZD0530 and bosutinib
are dual SFK/Abl inhibitors. Dasatinib, which was FDA-
approved for treatment of nonsolid tumors in June 2008, and
AZD0530 are in Phase II clinical trials for SCCHN. Bosutinib
and XL999 are in Phase II clinical trials for other cancers
(Table 3). However, XL999, which inhibits VEGFR, PDGFR
and FGFR in addition to Src kinases, was associated with
serious cardiovascular toxicities in Phase I and II clinical
trials [82–84]. Exelixis suspended new patient enrollment
in the ongoing XL999 clinical trials in November 2006.
A new addition to Src inhibitors in clinical development
includes the c-Src substrate competitive inhibitor, KX01,
which is currently being tested in phase I clinical trials. KX01
is exquisitely specific for c-Src whereas other Src-targeting
agents inhibit other SFK in addition to c-Src [85–87]. To date
there are no reports of Src-targeted therapeutics in SCCHN
clinical trials or molecular predictors of response to Src-
targeted therapies in patients with solid malignancies.
7. Cotargeting of EGFR and Src Family
Kinases in Patients
Combining EGFR- and Src-targeted therapies for SCCHN
is supported by results from preclinical studies. Our group
reported that combined AZD0530 and gefitinib treatment of
SCCHN cell lines in vitro resulted in significantly reduced
cell growth and invasion compared to single agent treatments
[88]. De novo and acquired resistance to cetuximab are
means by which SCCHN patients fail therapy.
SCCHN and NSCLC preclinical models selected for
resistance to cetuximab in vitro have been reported to have
high levels of activated SFK and to have decreased PI3K/Akt
activity following dasatinib treatment [89]. Interestingly,
these cetuximab resistant cells were found to be resensi-
tized to cetuximab following treatment with dasatinib [89].
These data in addition to our current understanding that
many EGFR-independent cell signaling pathways, including
GPCR- and integrin-initiated pathways, are modulated at
least in part by SFK provide the rationale for the combined
targeting of EGFR and SFK for treatment of SCCHN.
To date, there are no published reports of combined
EGFR- and Src-targeted therapies for treatment of patients
with solid tumors. Three clinical trials combining EGFR-
and Src-targeted therapies for upper aerodigestive cancers
are currently ongoing. A Phase I trial combining dasatinib
with erlotinib in patients with recurrent NSCLC is ongoing
at the H. Lee Moffitt Cancer Center and Research Institute
(NCT00444015, ClincalTrials.gov). A Phase I/II study in
NSCLC also combining dasatinib with erlotinib is ongoing
at M.D. Anderson Cancer Center (NCT00826449, Clinical-
Trials.gov). Our group will soon open a Phase 0 biomarker
modulation study combining erlotinib with dasatinib for
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patients with SCCHN or NSCLC (NCT00779389, Clinical-
Trials.gov). Results from these trials are not yet available.
Our group recently completed a Phase I trial combining
cetuximab with dasatinib for treatment of advanced solid
malignancies (NCT00388427, ClinicalTrials.gov). Seventeen
of 25 patients enrolled in our Phase I study were evaluable
for response, and 9 had stable disease while head ache
was a primary toxicity [90]. We have evaluated molecular
correlates in these patients and found that P-SFK levels in
peripheral blood mononuclear cells were transiently reduced
following daily dasatinib dosing (unpublished data). In
addition, we found that EGFR, TGF-α, and amphiregulin
plasma levels were altered following treatment (unpublished
data). A Phase II study combining dasatinib and cetuximab
for treating SCCHN patients is planned at the University of
Pittsburgh Cancer Institute. Results frommolecular correlate
studies from this trial and others will be of great importance
as the SCCHN medical and research communities work to
identify predictive molecular markers of response to these
therapies.
8. Summary and Future Directions
Despite the ubiquitous expression of EGFR in SCCHN,
clinical responses to EGFR targeting agents, particularly,
when administered as single agents, has been modest.
Cetuximab was FDA-approved in 2006 for the treatment
of newly diagnosed SCCHN in combination with radiation
and recently extended to the recurrent/metastatic popu-
lation in combination with chemoradiotherapy. However,
in most of these trials, expression levels of EGFR in the
tumor have not correlated with response to cetuximab
and no single biomarker to date in baseline tissue has
been proven to predict response to EGFR targeting agents.
Comprehensive genomic and proteomic studies of baseline
tissue are required in the context of clinical trials to
begin to identify potential markers of clinical activity. Since
EGFR signaling involves intracellular interactions with other
oncogenic pathways in SCCHN preclinical models, it is
plausible that cotargeting of EGFR in conjunction with
blockade of these pathways may be beneficial. Src family
kinases represent a potential pathway for targeting, especially
given the FDA-approval of the Src kinase inhibitor dasatinib
for hematopoietic malignancies. Studies are underway to test
this hypothesis in SCCHN patients. Challenges include: (1)
the difficulty of testing antiinvasive/antimetastatic agents in
clinical trial settings, and (2) the possibility that RECIST
criteria may not reflect decreased tumor proliferation,
metabolism, or increased apoptosis as evidence by studies
that have incorporated PET tracers. More relevant endpoints
in EGFR-/Src-targeted trials than tumor shrinkage may
include time to progression or overall survival. This may be
especially relevant for locoregional recurrence/metastases in
SCCHN [91].
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